FabRx completes a clinical study for the treatment of a rare metabolic disease in children using 3D printed dosage forms

April 11, 2019 | Featured

In this world first study, FabRx’s personalised medicine 3D printer was integrated into a clinical setting to treat a rare metabolic disorder in paediatrics. Their 3D printing technology was used in the Pharmacy Department of the Clinic University Hospital in Santiago de Compostela to enable the on demand production of tailored dosage forms in response to each patient’s clinical requirements. This innovation enabled the production of tablets in a variety of dosages, colours and flavours, which were evaluated for patient acceptability and therapy control. The researchers found that 3D printing enabled a tighter control over target blood concentrations compared with the standard therapy, and that the flavours and colours of the 3D printed dosage forms were well accepted amongst all patients.

Mª Luz Couce Pico, the Director of the Diagnosis and Treatment of Congenital Metabolic Diseases Unit, commented that “Personalised 3D printed medicines has enabled an improved therapeutic and dietary adherence whilst optimising metabolic control.”

Chema Giráldez Montero, a specialist Paediatric Pharmacist at Clinic University Hospital of Santiago de Compostela, added that “3D printing is an innovative alternative to classic compounding that gives us the opportunity to develop personalised treatments for paediatric patients”

Dr Alvaro Goyanes, Co-founder and Director of Development, at FabRx stated that ‘We are delighted that our 3D printing technology is being used to benefit patients in this world first study. We are looking forward to applying our innovation to other disease areas in the future.’

The study will be published later in 2019.

Back to News

Copyright © 2021 FabRx Ltd